The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to FibroGen's FG-3019, the human monoclonal antibody against connective tissue growth factor (CTGF), for the treatment of idiopathic pulmonary fibrosis (IPF). CheckOrphan. 08/02/12. (Also see: Pulmonary Fibrosis Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.